Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 9
1996 7
1997 5
1998 1
1999 4
2000 3
2001 1
2002 7
2003 5
2004 7
2005 3
2006 5
2007 1
2009 3
2010 2
2011 6
2012 5
2013 10
2014 4
2015 6
2016 5
2017 4
2018 8
2019 8
2020 5
2021 5
2022 8
2023 3
2024 6
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D. Levey AI, et al. Among authors: edland sd. Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452. Brain. 2022. PMID: 34919634 Free PMC article. Clinical Trial.
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
Coughlin DG, Shifflett B, Farris CM, Ma Y, Galasko D, Edland SD, Mollenhauer B, Brumm MC, Poston KL, Marek K, Siderowf AD, Soto C, Concha-Marambio L; as the Investigators of the Parkinson's Progression Marker Initiative. Coughlin DG, et al. Among authors: edland sd. Neurology. 2025 Mar 11;104(5):e210279. doi: 10.1212/WNL.0000000000210279. Epub 2025 Feb 6. Neurology. 2025. PMID: 39913882 Free PMC article.
Imaging the Alzheimer brain.
Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, Sabri O, Adamson MM, Coburn KL, Olichney J, Schuff N, Spielman D, Edland SD, Black S, Rosen A, Kennedy D, Weiner M, Perry G. Ashford JW, et al. Among authors: edland sd. J Alzheimers Dis. 2011;26 Suppl 3(0 3):1-27. doi: 10.3233/JAD-2011-0073. J Alzheimers Dis. 2011. PMID: 21971448 Free PMC article.
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
Feldman HH, Luchsinger JA, Léger GC, Taylor C, Jacobs DM, Salmon DP, Edland SD, Messer K, Revta C, Flowers SA, Jones KS, Koulman A, Yarasheski KE, Verghese PB, Venkatesh V, Zetterberg H, Durant J, Lupo JL, Gibson GE; ADCS BenfoTeam Study Group. Feldman HH, et al. Among authors: edland sd. PLoS One. 2024 May 29;19(5):e0302998. doi: 10.1371/journal.pone.0302998. eCollection 2024. PLoS One. 2024. PMID: 38809849 Free PMC article.
Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ; Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment (ISTAART). Jicha GA, et al. Among authors: edland sd. Alzheimers Dement. 2022 Jun;18(6):1109-1118. doi: 10.1002/alz.12461. Epub 2021 Sep 29. Alzheimers Dement. 2022. PMID: 34590417 Free PMC article.
142 results